Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.
Actively Recruiting
Researchers are evaluating the efficacy and safety of NIO752 in people with Progressive Supranuclear Palsy PSP in this Phase III randomized, placebo-controlled study. The trial aims to understand how well NIO752 works in treating PSP Richardson syndrome, a condition characterized by certain neurological symptoms with onset less than 5 years ago. Participants with mild to moderate PSP and specific functional abilities are included to assess the treatments impact. Participants will be randomly assigned in a 21 ratio to receive either NIO752, an antisense oligonucleotide solution, or a placebo solution. This double-blind treatment phase is followed by an open-label extension where all participants can continue receiving NIO752. The study measures changes in disease severity and function over 72 weeks using several scales and cognitive tests. During the study, participants and their reliable study partners will attend visits for assessments including neurological exams, cognitive tests, and brain MRI scans. Researchers will monitor changes in PSP rating scales, daily living activities, cognitive function, and relevant biomarkers in cerebrospinal fluid. Safety is closely tracked through adverse event reporting. The total study duration includes 72 weeks of treatment followed by long-term monitoring until study completion.
Actively Recruiting
Tremors, such as those experienced by patients with Parkinsons disease and essential tremor, can be resistant to medication, leading to early use of invasive treatments like deep brain stimulation. There are few effective non-drug treatment options available, and tremors often severely limit daily activities, requiring support from caregivers. This research evaluates the use of the VILIM ball device, a portable, non-invasive vibrating therapy ball designed to reduce hand tremors temporarily and improve everyday functioning in patients with various tremor syndromes. The study compares the effects of the VILIM vibrating therapy ball when active Ball-On versus inactive Ball-Off in patients with Parkinsons tremor, essential tremor, and other tremor types. The device is customized during a training phase to the patients tremor and is intended for use at home or in professional settings. The therapy aims to reduce tremor intensity up to 50%, with effects lasting up to four hours, potentially helping patients perform tasks like eating and writing more easily. Participants will undergo assessments before and after using the therapy ball, including physician and patient evaluations using Clinical Global Impression Severity and disease-specific tremor scales such as MDS-UPDRS III and TETRAS. Tremor analysis data from accelerometers and functional tests like mini darts, writing tasks, and daily activities will also be collected. Independent physicians will review video recordings of evaluations in a single-blinded manner. The study measures the impact on tremor and daily function over a two-year period, with involvement in various tests and observation of therapy effects.
Actively Recruiting
This research aims to systematically record the results of routine laryngeal examinations and specific swallowing difficulties in patients with various neurodegenerative diseases such as Multiple System Atrophy MSA, Progressive Supranuclear Palsy PSP, Parkinsons Disease, Motor Neuron Disease MND, and other related conditions. These disorders often lead to swallowing problems known as dysphagia, which can cause serious complications like dehydration, malnutrition, and pneumonia. The study seeks to better understand how these swallowing issues vary with different disease types and stages. Participants undergo a fiberoptic or flexible endoscopic evaluation of swallowing FEES using a structured task protocol designed to assess laryngopharyngeal function. When available, laryngeal electromyography EMG results are also collected. The study includes patients diagnosed according to established diagnostic criteria for their specific neurodegenerative disorder. Data collected also include demographic information and disease-specific details, along with responses to two questionnaires assessing swallowing disturbances and quality of life related to swallowing. During the study, participants will have their swallowing function assessed through FEES and complete questionnaires about their swallowing difficulties and quality of life. Researchers will evaluate laryngeal movement disorders and dysphagia as primary outcomes. This observational study does not involve any treatment intervention and aims to follow participants over time to categorize swallowing issues and correlate them with their disease subtype. The study has been ongoing since 2017 and plans to continue recruitment and data collection through 2028.